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Abstract
At present, IPMN is broadly divided into two main types: main duct and branch duct. However, as 
discussed below, the definition of mixed-type IPMN is gradually becoming accepted. In main duct 
IPMN, the main pancreatic duct is very dilated, while in branch duct IPMN, the branches of the 
pancreatic duct are dilated, resembling a bunch of grapes.
IPMN is most frequently diagnosed in the elderly (around 65 years old), and the male to female ratio 
is 2:1, indicating that the incidence of the disease is twofold higher in males than in females. IPMN 
most commonly originates in the head of the pancreas, and approximately 70% of IPMN lesions are 
found in the head of the pancreas. It also tends to occur in multiple sites. 
With regard to imaging, endoscopy has revealed that the opening of the papilla of Vater, located in 
the duodenum close to the stomach, is dilated by mucus. This dilation of the papillary opening of 
Vater by mucus is a key characteristic of IPMN. When directly viewed by pancreatoscopy, IPMN 
appears as small protrusions similar to salmon roe.
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1. IPMN as a cystic disease of the pancreas: 
classifications and status
C o n v e n t i o n a l l y ,  t h e  t e r m  ‘ c y s t ’ i s 
clinicopathologically defined as ‘a closed cavity 
containing a liquid or semi-solid substance’. 
Therefore, by definition, a pancreatic cyst has 
no communication with the pancreatic duct, and 
this has been considered as an important element 
in the concept of cystic disease of the pancreas. 
However, even typical pancreatic ‘cysts’ may 
exhibit communication with the pancreatic duct 
that increases the intraductal pressure either 
during endoscopic retrograde pancreatography 
(ERP) or during pancreatography of a resected 
specimen. Moreover, it is justifiable to consider the 
pancreatic duct as the origin of retention cysts, 
cystic neoplasms and cystic disease of the pancreas. 
Therefore, it can be assumed that originally, there 
was communication with the pancreatic duct, which 
means that the status of communication with the 
pancreatic duct may not always be necessary in 
defining cysts. 
Furthermore, advances in imaging diagnosis 
over the past 20 years have enabled extensive 
visualisation of cystic dilatory lesions of the 
pancreas. Consequently, these lesions are now 
treated as cystic lesions of the pancreas, regardless 
of the status of communication with the pancreatic 
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duct [1, 2]. 
Cysts with an epithelial lining of the cystic lumen 
are true cysts, while those without an epithelial 
lining are pseudocysts. Neoplastic cysts (cystic 
neoplasms of the pancreas) are true cysts and 
include serous cystic neoplasm (SCN), mucinous 
cystic neoplasm (MCN) and intraductal papillary 
mucinous neoplasm (IPMN) [3,4]. 
From a clinicopathological perspective, IPMN 
is now more widely accepted than the mucus-
producing pancreatic cancer proposed by Ohashi 
et al. in 1982 [5], and such cases were later reported 
in the 1980s. There have been several debates on 
the establishment of the concept of IPMN as a 
disease in Japan. Thereafter, around 1990, the 
concept became established worldwide following 
the publication of the fourth edition of the 
regulations on handling pancreatic cancer in Japan 
[6], the Armed Forces Institute of Pathology (AFIP) 
publication on tumours of the pancreas [7] and the 
World Health Organization (WHO) classification of 
pancreatic tumours [8]. As a result of establishing 
the concept of the disease and the frequent 
discovery of the disease in clinicopathological 
practice in Japan, IPMN is considered to have 
originated in Japan and gradually been recognised 
internationally. Following various international 
debates, the first version of the IPMN/MCN 
international consensus guidelines [9] was published 
in 2006. Six years later, in 2012, the second version 
[10] was published. International awareness of IPMN 
with regard to its course, classification, definition 
and surgical indications continues to develop with 
new reviews and revisions. 
In the past ,  there have been a number of 
classifications of pancreatic cysts, including those 
by Howard and Jordan [11], Strodel and Eckhauser 
[12], Cubilla and Fitzgerald [13], Bradley [14], Howard [15] 
and Kuroda and Morioka [16]. However, the concept 
of IPMN as a dilated lesion of the pancreatic 
duct, which has now been established, does not 
incorporate the classification of a pancreatic cyst, 
which is now considered outdated. Instead, the 
latter is considered a practical classification that 
incorporates the concept of IPMN.
2. Diagnosis and challenges of IPMN
To improve the understanding of cystic neoplasms 
of the pancreas and IPMN, it is important to 
clarify differences in the concepts of IPMN and 
MCN and to differentiate between the two. Until 
the latter half of the 1990s, there was ongoing 
debate on where to draw the line between main 
duct and branch duct IPMNs and MCN and no 
consensus was reached regarding the diagnosis and 
treatment of cystic neoplasms of the pancreas. 
There have been a number of discussions, including 
whether IPMN and MCN should be considered as 
different diseases or congeneric diseases. In both 
MCN and IPMN, the pancreatic duct is dilated 
to form a cyst and mucus is produced (Fig. 1) [1]. 
In addition, both are derived from the pancreatic 
duct epithelium and therefore exhibit the same 
Fig. 1 Demarcation between MCN and branch duct 
IPMN
Similar to MCN and serous cystic tumour, branch 
duct IPMN is often treated as a cystic disease of 
the pancreas. However, there has been resistance 
against placing main duct IPMN in the class of 
cystic disease of the pancreas. Moreover, IPMN 
and MCN have the common attribute of mucus 
production; however, MCN and IPMN are clearly 
different diseases clinicopathologically. Therefore, 
it is very important to differentiate and draw a 
line between MCN and branch duct IPMN. The 
lack of consensus on where to place the line of 
differentiation between MCN and branch duct 
IPMN has been a cause of confusion [1].
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histology. However, there are marked differences 
in the clinicopathological characteristics, such 
as age of onset, gender, site of onset, presence or 
absence of ovary-like stroma, capsule structure, 
communication with the pancreatic duct and 
concomitant pancreatitis. In other words, as the 
Japan Pancreas Society Subcommittee has clearly 
stated with regard to pancreatic cyst classification, 
MCN and IPMN are clearly different diseases 
clinicopathologically. In particular, the presence 
of fibrous membranes and ovary-like stroma in 
the septal wall, as revealed histologically, has been 
reported in many cases of MCN (86%) [17]. Therefore, 
the fact that ovary-like stroma is never observed in 
IPMN has become recognised as a definitive finding 
that shows that IPMN and MCN are different 
diseases. Following this, another issue was the 
clarification of where the line should be drawn 
between branch duct IPMN and MCN (Fig. 1) [1] and 
where the two are positioned in the classification of 
pancreatic cysts and the classification of exocrine 
pancreatic tumours [1]. 
Moreover, whether the presence of ovary-like 
stroma is an absolute requirement in the definition 
of MCN remained a topic of discussion. In medical 
practice, differential diagnosis should be made 
before surgery, following which indications 
for surgery are decided. In addition, it has 
been suggested that it is better to differentiate 
IPMN from MCN by imaging. In other words, 
the tumours should be defined on the basis of 
diagnostic imaging or macroscopically as follows: 
‘macroscopically, MCN is spherically shaped and 
has a characteristic fibrous capsule where the entire 
cyst is enclosed, and branch duct IPMN consists 
of a collection of dilated pancreatic duct branches 
where the outline is not spherical but irregular’ [18]. 
In other words, in terms of imaging diagnostics, 
MCN can be characterised as ‘a summer orange’ 
and branch duct IPMN as ‘a cluster of grapes’ (Fig. 
2) [19]. 
Zamboni et al. [17],  who suggested a strong 
relationship between MCN and ovary-like stroma, 
also reported that 14% of MCNs do not have an 
ovary-like stroma and that these MCNs have a 
stronger tendency to infiltrate than those with 
an ovary-like stroma. The opinion that ‘the 
classifications must be performed by diagnostic 
imaging before  surgery’ was not  c lear ly 
documented in the first published IPMN/MCN 
international guidelines [9] on whether macroscopic 
classification of main duct, branch duct and mixed-
type IPMNs should be performed by diagnostic 
imaging or histologically but it is documented in 
the second edition [10]. Because this is important 
while establishing a treatment policy, it is 
stipulated that macroscopic classification must be 
performed by diagnostic imaging before surgery. 
For  MCNs without  an  ovary- l ike  stroma 
c l i n i c o p a t h o l o g i c a l l y ,  t h e  e x p r e s s i o n 
‘indeterminate mucin-producing cystic neoplasm 
Fig. 2 MRCP image of branch duct IPMN showing 
how it resembles a bunch of grapes. 
Fig. 3 MRCP image of main duct IPMN.
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of the pancreas’ was proposed on the basis of our 
recommendation currently in preparation by the 
First Department of Surgery team. 
3. At present, IPMN is mainly divided into two 
types: main duct (Fig.3) and branch duct. However, 
as discussed below, the definition of mixed-type 
IPMN is gradually being accepted. In main duct 
IPMN, the entire main pancreatic duct is very 
dilated, whereas in branch duct IPMN, the branches 
of the pancreatic duct are dilated, resembling 
a bunch of grapes. IPMN is most frequently 
diagnosed in the elderly, aged around 65 years, 
and the male to female ratio is 2:1, indicating that 
its incidence is twofold higher in males than in 
females. IPMN most commonly originates in the 
head of the pancreas, and approximately 70% of 
tumours are found in the head of the pancreas. It 
can also occur in multiple sites. 
Endoscopy has revealed that the opening of 
the papilla of Vater, located in the duodenum 
close to the stomach, is dilated by mucus. This 
dilation of the papillary opening by mucus is a 
key characteristic of IPMN. When directly viewed 
by pancreatoscopy, IPMN appears as small 
protrusions similar to salmon roe. Findings of 
endoscopic retrograde cholangiopancreatography 
(ERCP) have revealed a radiolucent image of mucus 
in the main pancreatic duct. Magnetic resonance 
imaging (MRI) may reveal a mass resembling a 
bunch of grapes, as described previously, indicating 
branch duct IPMN. Observation of the interior of 
the cyst by endoscopic ultrasound (EUS) may reveal 
nodular protruded lesions in the cyst, and these 
findings indicate the need for surgery. Incision of 
the pancreas during surgery is known to result 
in leakage of copious amounts of mucus from the 
main pancreatic duct. This mucus is collected and 
placed into a Petri dish, where it can be examined. 
The clinical confirmation of the presence of mucus 
is an important marker in the diagnosis of IPMN.
 
With regard to symptoms and complications 
associated with IPMN, acute pancreatitis accounts 
for approximately 18% of complications, multiple-
organ malignancies for 18% － 30% and conventional 
pancreatic cancer for approximately 3%. In 
addition, IPMN tends to recur in the remaining 
pancreas after surgery. Furthermore, when there 
is disease progression with infiltration of the 
periphery, IPMN can present as jaundice.
IPMN can be divided into four tissue subtypes, 
namely gastric,  intestinal,  bil iopancreatic 
ductal and neoplastic cell types. Of these, the 
prognosis after tumour resection is known to 
be comparatively favourable for the gastric and 
intestinal cell types.
The correlation between the grade of IPMN and 
cellular proliferation factor is indicated by the 
expression of Ki-67. The lower the IPMN grade, the 
lower is the level of Ki-67. On the other hand, the 
greater the seriousness of the condition, the higher 
is the level of Ki-67. 
With regard to the correlation between IPMN 
intraductal volume and the grade of malignancy, 
when the intraductal volume is determined by CT, 
the larger the volume, the higher is the grade of 
malignancy. 
Our experience in cases of IPMN resection is now 
discussed. We have performed IPMN resection 
on 109 patients. Of these, 21 (approximately 20%) 
had IPMN-induced infiltrative cancer and three 
(approximately 3%) had concomitant conventional 
pancreatic cancer. 
After IPMN resection, the overall 5-year survival 
rate was approximately 90%, which is a very good 
survival rate. However, when the condition had 
progressed to IPMN-induced infiltrative cancer, 
the 5-year survival rate was considerably worse 
(less than 60%). Therefore, it is important to resect 
IMPN before it becomes infiltrative. In addition, 
IPMN removed at the pre-infiltrative stage might 
also fall into the category of early pancreatic 
cancer. Surgery of the pancreas is divided into two 
main types: pancreaticoduodenectomy, in which 
surgery is performed on pancreatic head lesions, 
IPMN of the Pancreas
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and distal pancreatectomy, in which surgery is 
performed on lesions in the distal part of the 
pancreas. 
4. Future advances and challenges of IPMN
The revised version of the international guidelines 
on IPMN/MCN (2nd edition) was published in 
2012[10], and important clinical research on IPMN is 
ongoing. 
1. The incorporation of tissue subtypes in the 
2012 guidelines [10] has increased the possibility of 
predicting the grade of malignancy in the future 
using the pancreatic fluid obtained during ERCP 
as a test sample. Till date, there is no decisive 
guideline for judging the grade from examination 
of the pancreatic fluid. Moreover, with regard to 
pancreatic fluid carcinoembryonic antigen (CEA), 
the concentration in the pancreatic fluid flowing 
in the pancreatic duct differs from that in the fluid 
present in the cyst. The significance of diagnosing 
malignancy on the basis of these findings is an 
issue for future research.
2. As usual, nodular protrusion of the cyst wall is 
an important index of malignancy.
3. To stratify the risk of malignancy, worrisome 
features that lead to suspicion of malignancy 
(obscure diagnostic findings) have been newly 
defined in addition to high-risk stigmata (clear 
diagnostic findings), which is strongly suggestive 
of malignancy [10]. In the first edition, mural 
nodules, dilatation of the main pancreatic duct 
and positive cytodiagnosis were documented as 
high-risk stigmata [9]. In the 2012 edition, the 
content of the cyst on imaging, a main pancreatic 
duct diameter ≥10 mm and cystic lesions of the 
pancreatic head as a result of obstructive jaundice 
were added to the list of high-risk stigmata. 
The first edition of the guidelines stated that 
the question of whether branch duct IPMN with 
a cyst diameter of at least 30 mm and without 
mural nodules should be immediately considered 
for surgery was an issue for future investigation 
(Fig. 3) [9]. However, in the 2012 edition, this stage 
of disease has been defined as a worrisome feature, 
which should be observed (it has dropped one step 
below an indication for surgery). In addition, with 
regard to the indications for main duct surgery, in 
the 2012 edition, a dilation of the main pancreatic 
duct of at least 6 mm is defined as main duct. A 
main pancreatic duct diameter of at least 10 mm 
is defined as a high-risk stigmata and considered 
as an indication for surgery. IPMN with a main 
pancreatic duct diameter of 5 － 9 mm is defined as 
a worrisome feature, for which closer examination 
is recommended.
With regard to the definition of malignancy, in 
the WHO classification revised in 2010, in situ 
carcinoma has been defined as IPMN with high-
grade dysplasia [23]. Similarly, in the 2012 version of 
the guidelines, in situ carcinoma has been defined 
as IPMN with high-grade dysplasia. Although 
the guidelines do not state that IPMN with high-
grade dysplasia is in situ carcinoma or noninvasive 
carcinoma, caution is required because it could 
be interpreted that only infiltrative cancer is 
malignant. As clinicians, our aim is to resect as 
many malignant tumours as possible. Based on the 
prognosis, the best approach is to diagnose IPMN 
at the in situ carcinoma or noninvasive carcinoma 
stage and to perform early resection.
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